Wanbury Limited, a leading pharmaceutical company with a global footprint in active pharmaceutical ingredients (APIs) and domestic branded formulations, has announced a stellar financial performance for the second quarter of FY25. The company reported an 11.6% increase in revenue from operations, reaching ₹161.2 crore, compared to ₹144.5 crore in Q2 FY24. Its EBITDA jumped by […]
IOL Chemicals and Pharmaceuticals Limited (IOLCP), a leader in pharmaceutical active pharmaceutical ingredients (APIs) and specialty chemicals, recently reported its financial performance for Q2 FY25, revealing a revenue rise tempered by shrinking margins. In a disclosure to the National Stock Exchange of India and BSE Limited, the company shared key details about its recent earnings, […]
Zydus Lifesciences Limited has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for ZITUVIMET, a combination of Sitagliptin and Metformin hydrochloride, designed to improve glycemic control in adults with type 2 diabetes mellitus as part of a comprehensive lifestyle intervention. ZITUVIMET: A New Adjunct in Diabetes Care With the […]
In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim International GmbH. These brands, which Lupin has been marketing since 2015 under a co-marketing arrangement, come with the added bonus of trademark rights. India grapples […]
In a significant development for diabetes treatment in the U.S., Dr. Reddy’s Laboratories has unveiled its Saxagliptin and Metformin Hydrochloride Extended-Release Tablets. This launch introduces a therapeutic equivalent to the widely prescribed KOMBIGLYZE XR (saxagliptin and metformin hydrochloride extended release) tablets, with the endorsement of the US Food and Drug Administration (FDA). The Indian pharmaceutical […]
TheracosBio announced the publication of a 24-week randomized, double-blind, placebo-controlled trial, proving Bexagliflozin’s effectiveness as an adjunct to Metformin for treating adults with type 2 diabetes. The Phase 3 study, published in “Diabetes, Obesity and Metabolism,” highlights the positive impact of BRENZAVVY (bexagliflozin), 20 mg, in improving glycemic control and reducing systolic blood pressure levels. […]
Zydus Lifesciences said that its subsidiary Zydus Pharmaceuticals (USA) has been granted tentative approval for Canagliflozin and Metformin Hydrochloride Tablets, 50mg/500mg, 50mg/1,000mg, 150mg/500mg, and 150mg/1,000mg from the US States Food and Drug Administration (FDA). The Canagliflozin and Metformin Hydrochloride regimen is a generic version of Invokamet Tablets. It is intended to be used as an […]
AstraZeneca Pharma India (AstraZeneca India) said that it has scrapped its distribution agreement with Abbott Healthcare pertaining to its Type 2 diabetes drug Dapagliflozin in India. As per an agreement signed in late 2018, Abbott Healthcare had been promoting and distributing Dapagliflozin under the “Gledepa” brand name and the Dapagliflozin and Metformin combination under the […]